Senter for internasjonal helse


There has not been added a translated version of this content. You can either try searching or go to the "area" home page to see if you can find the information there

SAMBULELO Phase II double blind randomised placebo-controlled clinical trial.

There is increasing evidence that antibody, in particular neutralizing antibody, has the potential to prevent infection with HIV. This study will provide information on the safety and levels of one such neutralizing antibody in babies, paving the way to further studies.


A new category of medicines, broadly neutralizing monoclonal antibodies (bNAbs), stop the virus before it enters a cell, and thus work like vaccination. bNAbs last for a long time in the blood. This means that they do not have to be given every day – this is different from ARVs which need to be taken every day.

The study aims to characterize the safety and pharmacokinetics of the long-acting broadly neutralizing HIV antibody (bNAb) VRC07-523LS among breastfed HIV-exposed uninfected infants and HIV-infected breastfed infants receiving standard of care ART for prophylaxis or treatment.

These results will allow us to do larger studies to measure whether these antibodies prevent HIV transmission from mother-to-baby and whether they are useful in treating HIV-infected children.

The SAMBULELO Trial is complementary to another trial conducted by the same investigators, the Phase 1/2 PedMAb study. These two trials are meant to prepare for a phase 3 tolerance and efficacy trial.